Chronic idiopathic urticaria for the generalist

European Journal of Internal Medicine

Volumn 14, Issue 3, 2003, Pages 148-157

  Ortonne, Jean Paul ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Antihistamine; Desloratadine; Efficacy; Review; Safety; Sedation; Urticaria

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; ANTIPRURITIC AGENT; ASTEMIZOLE; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CETIRIZINE; CHLORPHENIRAMINE; DESLORATADINE; DIPHENHYDRAMINE; EBASTINE; EPHEDRINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR; IMMUNOGLOBULIN E RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; KETOCONAZOLE; LEVOCETIRIZINE; LORATADINE; MIZOLASTINE; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROMETHAZINE; TERBUTALINE; TERFENADINE;

ANGIONEUROTIC EDEMA; BASOPHIL; BLOOD VESSEL PERMEABILITY; CARDIOTOXICITY; CHRONIC IDIOPATHIC URTICARIA; CHRONIC URTICARIA; HUMAN; MAST CELL; PATHOPHYSIOLOGY; PATIENT CARE; PRURITUS; QUALITY OF LIFE; REDUCTION; REVIEW; SEDATION; SIDE EFFECT; VASODILATATION;

EID: 0037940075     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0953-6205(03)00035-9     Document Type: Review

References (36)

1. Greaves M.W. Chronic urticaria. New Engl J Med. 332:1995;1767-1772.
2. Sabroe R.A., Greaves M.W. The pathogenesis of chronic idiopathic urticaria. Arch Dermatol. 133:1997;1003-1008.
3. Sibbald R.G., Cheema A.S., Lozinski A., Tarlo S. Chronic urticaria. Evaluation of the role of physical, immunologic, and other contributory factors. Int J Dermatol. 30:1991;381-386.
4. Greaves M. Chronic urticaria. J Allergy Clin Immunol. 105:2000;664-672.
5. Champion R.H., Roberts S.O., Carpenter R.G., Roger J.H. Urticaria and angio-oedema. A review of 554 patients. Br J Dermatol. 81:1969;588-597.
6. The diagnosis and management of urticaria: a practice parameter. Part II: Chronic urticaria/angioedema. Ann Allergy Asthma Immunol. 85:2000;532-544.
7. O'Donnell B.F., Lawlor F., Simpson J., Morgan M., Greaves M.W. The impact of chronic urticaria on the quality of life. Br J Dermatol. 136:1997;197-201.
8. Nightingale S.L. From the Food and Drug Administration. J. Am. Med. Assoc. 268:1992;705.
9. Okahara K., Murakami T., Yamamoto S., Yata N. Skin microdialysis: detection of in vivo histamine release in cutaneous allergic reactions. Skin Pharmacol. 8:1995;113-118.
10. Hide M., Francis D.M., Grattan C.E., Hakimi J., Kochan J.P., Greaves M.W. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. New Engl J Med. 328:1993;1599-1604.
11. Niimi N., Francis D.M., Kermani F., et al. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol. 106:1996;1001-1006.
12. Garmendia J.V., De Sanctis J.B., Zabaleta M., Aldrey O., Bianco N.E. Cytokines in chronic idiopathic urticaria. J Allergy Clin Immunol. 104:(1 Pt 2):2000;S42.
13. Monroe E.W. Chronic urticaria: review of nonsedating H1 antihistamines in treatment. J Am Acad Dermatol. 19:1988;842-849.
14. Pien L.C. Appropriate use of second-generation antihistamines. Cleve Clin J Med. 67:2000;372-380.
15. Ring J., Hein R., Gauger A. Desloratadine in the treatment of chronic idiopathic urticaria. Allergy. 56:(suppl 65):2001;28-32.
16. Slater J.W., Zechnich A.D., Haxby D.G. Second-generation antihistamines: a comparative review. Drugs. 57:1999;31-47.
17. Simpson K., Jarvis B. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs. 59:2000;301-321.
18. Kreutner W., Hey J.A., Anthes J., Barnett A., Young S., Tozzi S. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: Receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung. 50:2000;345-352.
19. Ring J., Hein R., Gauger A., Bronsky E., Miller B. The Desloratadine Study Group. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol. 40:2001;1-5.
20. Monroe EW. Desloratadine Study Group. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol. in press.
21. Patel P., Danzig M. Comparative efficacy and safety of loratadine and cetirizine in patients with chronic idiopathic urticaria. Adv Ther. 14:1997;318-322.
22. Monroe E.W., Daly A.F., Shalhoub R.F. Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines. J Allergy Clin Immunol. 99:1997;S798-S806.
23. Claritin (loratadine) prescribing information. 2000;Schering, Kenilworth, NJ.
24. Hey J.A., Del Prado M., Sherwood J., Kreutner W., Egan R.W. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects [see comments]. Arzneimittelforschung. 46:1996;153-158.
25. Renwick A.G. The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. Clin Exp Allergy. 29:(suppl 3):1999;116-124.
26. Cvetkovic M., Leake B., Fromm M.F., Wilkinson G.R., Kim R.B.O. ATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 27:1999;866-871.
27. Bailey D.G., Dresser G.K., Munoz C., Freeman D.J., Kim R.B. Reduction of fexofenadine bioavailability by fruit juices. Clin Pharmacol Ther. 69:2001;P21.
28. Banfield C., Gupta S., Marino M., Lim J., Affrime M. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet. 41:2002;311-318.
29. Ring J., Gauger A., Hein R. Clinical efficacy of desloratadine in chronic urticaria. Clin Drug Invest. 22:(suppl 2):2002;33-41.
30. Gauger A., Hein R., Ring J., et al. Rapid onset and durability of desloratadine in the treatment of chronic idiopathic urticaria. Poster presented at the 58th Annual Meeting of the American Academy of Dermatology; March 10-15, San Francisco, CA:2000.
31. 1 receptor antagonist: 2nd communication: Lack of central nervous system and cardiovascular effects. Arzneimittelforschung. 50:2000;441-448.
32. Banfield C., Herron J., Keung A., Padhi D., Affrime M. Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. Clin Pharmacokinet. 41:(suppl 1):2002;37-44.
33. Marino M., Glue P., Herron J.M., Statkevich P., Affrime M.B., Lim J. Lack of electrocardiographic effects of multiple high doses of desloratadine. Allergy. 55:(suppl 63):2000;279.
34. Banfield C., Hunt T., Reyderman L., Statkevich P., Padhi D., Affrime M. Lack of clinically relevant interaction between desloratadine and erythromycin. Clin Pharmacokinet. 41:(suppl 1):2002;29-35.
35. Gupta S., Banfield C., Kantesaria B., et al. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin Ther. 23:2001;451-466.
36. Rachelefsky G.S., Salmun L.M., Banfield C. Predictability of desloratadine: lack of clinical interaction with food and concomitant medications. J Allergy Clin Immunol. 107:2001;S162-S163.